A log-rank test and multivariable Cox models were used to assess associations. Patients with MDM4-rs10900598 GT/TT had a worse disease-free survival (DFS) compared with corresponding GG genotype, while those with rs11801299 AG/AA genotypes had a lower recurrence risk than the cases with rs11801299 GG genotype (both log-rank, P < 0.001). Multivariable analysis showed that significantly different recurrence risk were found among patients with MDM4-rs10900598 GT/TT and rs11801299 AG/AA variant genotypes (HR, 2.0, 95% CI, 1.4-2.9 and HR, 0.4, 95% CI, 0.3-0.6, respectively) compared with their corresponding common homozygous genotypes. Furthermore, after combining the risk genotypes of the three SNPs, patients among low-risk group had a significantly lower risk of SCCOP recurrence than those in high-risk group (HR, 0.2, 95% CI, 0.1-0. Recurrences of the primary tumor are the major cause of poor prognosis and mortality of SCCOP. A major challenge for the management of SCCOP is how to identify patients with high-risk recurrence for and optimally clinical treatment. Refining prognostic stratification is crucial to better individualize treatment in SCCOP for improved and less-toxic outcomes. 4 However, prognostic models based on current TNM staging system may not effectively predict the outcome of an increasing HPV-related SCCOP. 5 Outcomes for SCCOP patients with the similar TNM stage may vary significantly.
Thus, identifying new prognostic biomarkers to better accurately predict the risk of recurrence of SCCOP may lead to better treatment and survival.
Many studies have revealed that single nucleotide polymorphisms (SNP), may modify genetic susceptibility to development or outcomes of SCCOP, 6, 7 and could serve as reliable and efficient prognostic biomarkers to allow accurately identify SCCOP patients with high-risk of recurrence. 8, 9 p53, an important tumor suppressor protein, plays a critical role in genome integrity, acting as "the guardian of genome," 10 is mutated in about half of all human cancers, especially in SCCHN. 11, 12 p53 is mainly regulated by interaction with two negative modulators, mouse double minute 2 (MDM2) and 4 (MDM4), which inhibit the tumor suppressor activity of p53. at the initial of presentation. Detailed information about treatment and comorbidities has been described previously. 31 "Ever drinkers" were defined as subjects who had drunk alcoholic beverages at least once a week for more than 1 yr in their lifetime and the rest were categorized as "never drinkers." Participants who had smoked over 100 cigarettes during their lifetime were classified as "ever smokers," and otherwise as "never smokers." Genotyping of MDM4 SNPs were carried out using the Applied Biosystems TaqMan genotyping platform as described previously. 7 Approximately 10% of the specimens were randomly doublechecked for quality control, showing that genotype concordance rate was 100%.
To assess the combined effect of these three SNPs, we categorized all putative risk (aHRs > 
| Tumor HPV16 detection
Paraffin-embedded tumor tissue biopsies or specimens from enrolled patients were used to extract DNA for HPV16 detection using the specific PCR and in situ hybridization assay as described previously.
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A subset of samples (5%) were checked for tumor HPV16 status in duplicates for quality control. The results of these samples were 100%
concordant with the original ones.
| Plasmid constructs, transfection, and luciferase assays
The MDM4 rs10900598 (both T and G alleles) and rs11801299 (both A and G alleles) allelic reporter constructs were generated by amplifying a 633-bp and 675 fragment of the MDM4 3′-UTR region from subjects homozygous for the rs10900598 TT or rs10900598 GG genotype as well as rs11801299AA or rs11801299GG genotype.
The PCR products were separated, digested with Xba I (Promega, The univariate Kaplan-Meier analysis showed that patients, who were older than 57 years old (P < .0001), other ethnicity (P < .0001), ever smokers (P = 0.0004), and alcohol drinkers (P = 0.0005), had moderate to severe comorbidity (P = 0.0370), and received combined treatment of surgery with chemoradiotherapy (P = 0.0030), respectively, were significantly associated with DFS. However, no significant associations were observed between patients with and without recurrence according to other factors, including sex (P = 0.3110), index tumor stage (P = 0.5280). Table 2 showed that the genotypes distribution of three selected MDM4 polymorphisms, 5-year recurrence rates by genotype, and the associations between SNPs and recurrence risk in patients with SCCOP. Patients with the MDM4-rs10900598 GT/TT, MDM4-rs11801299 GG genotypes had significantly worse DFS compared with their corresponding GG and AG/AA genotypes (log-rank, P = 0.0002 and P < 0.001, respectively) ( Figure 1 ). The similar findings were found among 324 patients with HPV16-positive SCCOP (logrank, P = 0.051 for MDM4-rs10900598 and P = 0.029 for MDM4-rs11801299; Figure 1 ). In multivariable Cox proportional hazards regression analyses, the risk of disease recurrence differed significantly in patients carrying the MDM4-rs10900598 GT/TT and MDM4-rs11801299 GG genotypes compared with their corresponding GG and AG/AA genotypes (HR, 2.0, 95% CI, 1.4-2.9 and HR, 0.4, 95% CI, 0.3-0.6) after adjusted for some possible confounders (Table 2 ).
Given the roles of both MDM4 and HPV involving in the p53 pathway, we further evaluated the associations between genotypes of the three MDM4 polymorphisms and recurrence risk among 324 HPV16-positive SCCOP cases. Table 3 showed that patients with MDM4-rs10900598 GT/TT variant genotypes had a significantly higher recurrence risk than those with GG common homozygous genotype (aHR, 1.8; 95% CI, 1.0-3.9), while patients with MDM4-rs11801299 AG/AA had a significantly lower risk of recurrence than those carrying MDM4-rs11801299 GG common homozygous genotype (aHR, 0.4; 95% CI, 0.2-0.9). However, no significant association between MDM4-rs1380576 polymorphism and recurrence risk was 
| DISCUSSION
In the present study, we found 3 SNPs within the MDM4 genes that may play a critical role in predicting tumor recurrence of SCCOP patients. MDM4-rs10900598 and MDM4-rs11801299 variants may individually, or more likely jointly, significantly modulate the risk of SCCOP recurrence after adjusting for other important confounders, particularly in HPV16-positive tumors of SCCOP. To our knowledge, this study is the first to investigate the associations between MDM4
polymorphisms and increased risk of recurrence in SCCOP patients.
Our previous study 7 reported that combined effect of 3 MDM4
variants may be linked to the risk of SCCOP, particularly for HPV16-positive SCCOP. In the present study, we further provided evidence for a significant association between MDM4 variants and a modified risk of SCCOP recurrence. If our results are further validated, improved strategies based on these MDM4 genetic variants could be used to identify patients with higher recurrence risk. Therefore, there may be a better-tailored therapy and prevention regimen for SCCOP patients, which may contribute to better outcomes and lower adverse events.
The molecular mechanisms underlying the effects of MDM4-rs10900598 and MDM4-rs11801299 genetic variations on cancer recurrence are still not well understood. However, there are some plausible explanations. Recent study 33 has suggested that MDM2 FIGURE 1 Kaplan-Meier estimates for DFS of patients according to the MDM4-rs10900598 and MDM4-rs11801299 genotypes among all patients and those with HPV16-positive SCCOP might play a role in determining the risk of recurrence of SCCOP. As MDM4 has a strong similarity in gene sequence and structure to MDM2, it is conceivable that MDM4 may have the similar mechanism in modifying the recurrence risk of SCCOP.
Previous studies have shown that other genetic changes, such as amplification or overexpression, of MDM4 was associated with tumor progression and poor prognosis. 21, 30, 34, 35 Therefore, it is our specula- It has been known that HPV is an independent prognostic factor associated with prognosis of SCCOP. Our previous study indicated that both HPV16 E6 and MDM4 oncoproteins may function synergistically in the development and progression of HPV-positive SCCOP through the common pathways that cause p53 degradation due to HPV16 E6 binding to p53 and targets it for proteasomal degradation. 36 In this study, we found that the association were statistically significant between MDM4 variants and risk of recurrence Our findings are strengthened by some points. First, our study patient population was a well-defined cohort of SCCOP patients with the largest sample size and the careful quality control in genotyping.
Second, this is the first study to date to examine the effects of MDM4 Second, our study lacked detailed information on the exact radiotherapy dosage and duration for each SCCOP patient. Although the treatment of radiotherapy or chemotherapy was associated 5-year recurrence of SCCOP patients, while we found that there were no significant associations between treatment and these three MDM4 genetic variants. In addition, in this study treatment was also included as a covariate in the Cox regression model for MDM4 SNPs. Therefore, treatment is unlikely to be a confounder; and MDM4 variants appear to be independent prognostic factors for recurrence of SCCOP.
Furthermore, as our study had a relatively small number of SCCOP patients with HPV16-positive tumors and event outcome of recurrence, the finding could be due to chance. Finally, besides these three polymorphisms, some other possible genetic variants might be also evaluated in a large-scale and comprehensive study.
| CONCLUSIONS
In conclusion, our report provides the first evidence that the MDM4 genetic variants may individually, and more like jointly contribute to susceptibility to SCCOP recurrence risk, particularly in HPV16-positive tumors of SCCOP. However, further studies are needed to explore underlying mechanisms and further validate the clinical significance of these polymorphisms.
